Asia Fresh News

Asia Fresh Stories

Archive for August 25th, 2014

Cambodia Business Conference Expects Keen Interest from Asia as Registration Opens

leave a comment »

PHNOM PENH, Cambodia, Aug. 21, 2014 /PRNewswire/ — Cambodia’s business community is anticipating keen interest from investors in Asia as registration for the country’s international investment conference opens.

The International Business Chamber (IBC) of Cambodia investment conference will take place on October 6th and 7th at the Intercontinental Hotel in Phnom Penh. The event is expected to attract hundreds of overseas companies with an interest in investing in Cambodia.

“When it comes to economic growth, Cambodia is an unparalleled success story in Southeast Asia,” said IBC Chairman Bretton Sciaroni. “And now, with the 8th International Investment Conference, the International Business Chamber of Cambodia is offering the opportunity for overseas companies to come together with Cambodian political and economic leaders to explore the country’s continuing economic development.”

Cambodia’s Prime Minister Hun Sen will officially open the event.

Prudential Corporation Asia Chairman Donald Kanak has been named as a keynote speaker.

Topics for discussion at the event will include Cambodia‘ economic outlook as well as the country’s competitiveness. Speakers will include government ministers as well as CEO’s with experience of the Cambodian market.

“Almost every sector of Cambodia’s economy is represented,” added IBC Investment Conference Committee Chairman In Channy. “There will be representatives from Cambodia’s government as well as those from the business sector. The IBC expects that there will be many extremely meaningful and enlightening discussions.”

Platinum sponsors for the IBC conference are Prudential Cambodia, Jardine Matheson Limited, Sciaroni and Associates, ACLEDA Bank and ANZ Royal. Gold sponsors include DFDL and Ezecom.

The South East Asia Globe and its sister publication Focus ASEAN are media partners of the event.

Those wishing to register for the IBC Investment conference should visit the IBC’s website at www.ibccambodia.com.

Registration fees are USD 600 for non-IBC members and USD 500 for IBC members.

ABOUT THE IBC

The International Business Chamber of Cambodia (IBC) is an officially registered Association. The IBC was set up to provide leadership in creating a forum for international and local businesses and business associations having an interest in Cambodia. The IBC prides itself on fostering constructive relations with the Royal Cambodian Government to promote policies, laws and regulations conducive to the development of the business environment.

Please visit http://www.ibccambodia.com for further details about the IBC and the conference.

Source: The International Business Chamber of Cambodia (IBC)

Written by asiafreshnews

August 25, 2014 at 3:06 pm

Posted in Uncategorized

Investor Central Launches “Tycoon” Reports on Singapore and Malaysian Stocks, Especially for US and European Fund Managers

leave a comment »

SINGAPORE, Aug. 22, 2014 /PRNewswire/ — Investor Central, a service of Hong Bao Media, today launched a new class of ground-breaking equities research, which provides cutting edge local insights into Singapore– and Malaysia-listed companies, specially designed for fund managers outside of Asia.

Branded “Tycoon”, the forensic accounting reports are unique in that they offer candid insights and boots on-the-ground, which institutional investors outside of the region have difficulty accessing.

“Investor Central Tycoon reports alert investors to information gaps and asks the tough questions investors need to ask before making investment decisions”, said Mark Laudi, former CNBC anchor and Executive Editor, Investor Central.

“The market needs research that’s neither oriented around sell-side pressures, nor the need for analysts to forge cozy relationships with the companies they cover.

“Certain European regulators have been restricting the type of research which fund managers can expense. Investor Central recognises these limitations. Our Tycoon reports contain the substantive insights which contribute to their decision making.”

Tycoon reports include:

  • All questions we asked of the company, and answers we receive
  • Handshakes relationship maps tracking links between the researched company and other companies (including BVI and Cayman companies), individuals and events
  • Details of internal auditors
  • Brendan Wood International (BWI) Shareholder Confidence Index ranking
  • Candid photographs and maps
  • 1-year archive of earlier reports
  • Convenient index of sources of information

Other benefits which Tycoon subscribers receive:

  • Notification of the stocks being researched before publication
  • Priority access to the completed reports, 24 hours before everyone else
  • Up to thirty (30) minutes per month consultancy time with our researchers

“The corporate culture surrounding transparency are very different here in Asia than what U.S. and European investors are used to.

“This leaves non-Asian investors struggling for an accurate picture as to what’s really going on, on the ground,” Laudi concluded, “We can, and we serve as their eyes and ears on the ground. Our advantage is local knowledge and cultural understanding.”

Investors can find more information at http://www.investorcentral.org/tycoon.php

FOR FURTHER INFORMATION:

Shreya Shetty
Marketing Manager
Investor Central
contact@investorcentral.org
Tel. +65-6223-2249

ABOUT INVESTOR CENTRAL

Investor Central was launched in 2006 by former CNBC anchor Mark Laudi. Investor Central is part private research service, part news organisation, which promises to keep investments honest by asking the questions that need to be asked. Our small, qualified team of researchers are solely focused on researching and writing reports from a fundamental, value perspective.

Investor Central does not issue “buy” or “sell” calls, nor do we or our staff take short positions in the companies we research.

Investor Central has won numerous awards for its reports, including Best Example of Content Leadership at the Asian Publishing Convention for its “Dog or Darling” IPO reviews, and the Securities Investors Association Singapore’s Most Promising Financial Journalism Merit Award.

https://hongbaomedia-my.sharepoint.com/personal/mark_laudi_hongbaomedia_onmicrosoft_com/_layouts/15/guestaccess.aspx?guestaccesstoken=UgawFoafwtjHr%2bI8ia6pOaLbXLbBb2hmbzz6ZubnHnc%3d&docid=0c749bc9308164e4680ae62cfc5550b49

 

Source: Hong Bao Media

Written by asiafreshnews

August 25, 2014 at 2:43 pm

Posted in Uncategorized

SNC-Lavalin completes landmark acquisition of Kentz

leave a comment »

— A key milestone in SNC-Lavalin’s ongoing transformation into a global Tier-1 engineering and construction company

MONTREAL  /PRNewswire/ — SNC-Lavalin Group Inc. (TSX: SNC) is pleased to announce that it has completed its acquisition of Kentz Corporation Limited, a global company with 15,500 employees operating in 36 countries. Kentz provides industry-leading engineering, construction management and technical support services to clients in the oil and gas sector.

The acquisition of Kentz supports SNC-Lavalin’s ongoing transformation into a global Tier-1 engineering and construction (E&C) company. The transaction creates a group with approximately 45,000 employees, annual revenues of about C$10 billion and a backlog of roughly C$13 billion as per 2013 figures. The combined company will also have a strong position in the world’s most dynamic growth markets, including the Middle East,North America, Latin America and Asia-Pacific.

“SNC-Lavalin is thrilled to welcome the employees of Kentz, who are the heart and soul of the remarkable company we are acquiring today,” said Robert G. Card, President and CEO, SNC-Lavalin Group Inc. “We expect that our combined capabilities will give us one of the best broad-based service offerings in the E&C industry, while expanding our presence in key growth markets.”

Transformational growth in oil and gas
The acquisition of Kentz transforms SNC-Lavalin’s oil and gas capabilities, creating a group of approximately 20,000 high-caliber employees with industry leading expertise for large and complex projects in the upstream, liquefied natural gas (LNG), unconventional (shale gas and oil sands), pipelines, offshore jackets and steam-assisted gravity drainage (SAGD) sectors.

“We have now begun implementing our plan, which aims to ensure our teams are combined efficiently, respectfully and as rapidly as possible,” said Neil Bruce, President, Resources, Environment & Water, SNC-Lavalin Group Inc. “We will be bringing together the best capabilities of our two firms for the direct benefit of our clients. Our goal will be to build strong and lasting relationships with our customers through consistently delivering on our commitments and providing the best mix of value and services.”

Kentz will be incorporated into SNC-Lavalin while simultaneously integrating SNC-Lavalin’s current Oil & Gas business into Kentz’s operations. Christian Brown, Kentz’s Chief Executive Officer, now becomes President, Oil & Gas, SNC-Lavalin Group Inc. Mr. Brown will continue to be stationed in Houston, Texas, and will report directly toNeil Bruce.

“Joining SNC-Lavalin will provide us with the ability to execute larger scopes for major projects, and enhance our access to new geographies in both North America and Latin America,” said Christian Brown. “We look forward to bringing our clients complete end-to-end solutions for their projects by merging SNC-Lavalin’s strong front-end engineering and design capabilities with our industry-leading construction management, commissioning and operations capabilities.”

SNC-Lavalin paid £9.35 (C$17.13) per share for a total purchase price of approximately £1.2 billion (C$2.1 billion). Kentz shareholders voted in favour of SNC-Lavalin’s offer at a meeting convened by order of the Court and an Extraordinary General Shareholders Meeting, both held on August 11, 2014. The offer was structured as a Scheme of Arrangement and the Scheme Court Hearing was held on August 21, 2014. Following the sanction of the Court, the acquisition became effective in accordance with its terms on August 22, 2014.

Forward-looking statements
This press release contains statements that are or may be “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws. All statements other than statements of historical fact included in this press release may be forward-looking statements. Without limitation, any statements preceded or followed by or that include the words “targets”, “plans”, “believes”, “expects”, “aims”, “intends”, “will”, “should”, “could”, “would”, “may”, “anticipates”, “estimates”, “synergy”, “cost-saving”, “projects”, “goal” or “strategy” or, words or terms of similar substance or the negative thereof, are forward-looking statements. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, economic performance, indebtedness, financial condition, losses and future prospects; and (ii) business and management strategies and the expansion and growth of SNC-Lavalin or Kentz’s operations and potential synergies resulting from the transaction.

These forward-looking statements are not guarantees of future financial performance. Such forward-looking statements involve known and unknown risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. All subsequent oral or written forward-looking statements attributable to SNC-Lavalin or any of its directors, officers or employees or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. SNC-Lavalin disclaims any obligation to update any forward-looking or other statements contained herein, except as required by applicable law.

About SNC-Lavalin
Founded in 1911, SNC-Lavalin is one of the leading engineering and construction groups in the world and a major player in the ownership of infrastructure. From offices in over 50 countries, SNC-Lavalin’s approximately 45,000 employees provide EPC and EPCM services to clients in a variety of industry sectors, including oil and gas, mining and metallurgy, environment and water, infrastructure and power. SNC-Lavalin can also combine these services with its financing and operations and maintenance capabilities to provide complete end-to-end project solutions.
www.snclavalin.com

For further information:

Media:
Lilly Nguyen
Public Relations Manager,
Global Corporate Communications
SNC-Lavalin Group Inc.
+1-514-393-8000, ext. 54772
lilly.nguyen@snclavalin.com

Source: SNC-Lavalin

Related stocks: Toronto:SNC

Written by asiafreshnews

August 25, 2014 at 12:57 pm

Posted in Uncategorized

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

leave a comment »

LONDON  /PRNewswire/ — ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare’s first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

Triumeq alone is not recommended for use in patients with current or past history of resistance to any components of Triumeq. Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Products containing abacavir should not be used in patients known to carry the HLA-B*5701 allele.1

Dr Dominique Limet, Chief Executive Officer, ViiV Healthcare, said: “Today’s approval of Triumeq offers many people living with HIV in the US the first single-pill regimen containing dolutegravir. ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV. We are proud to announce this important milestone, marking the second new treatment to be approved in the US from our pipeline of medicines.”

This FDA approval is based primarily upon data from two clinical trials:

  • the Phase III study (SINGLE) of treatment-naive adults, conducted with dolutegravir and abacavir/lamivudine as separate pills2,3
  • a bioequivalence study of the fixed-dose combination of abacavir, dolutegravir and lamivudine when taken as a single pill compared to the administration of dolutegravir and abacavir/lamivudine as separate pills.4

In the SINGLE study, a non-inferiority trial with a pre-specified superiority analysis, more patients were undetectable (HIV-1 RNA <50 copies/mL) in the dolutegravir and abacavir/lamivudine arm (the separate components of Triumeq) than in the Atripla®+ (efavirenz, emtricitabine and tenofovir) arm, the most commonly used single-pill regimen. The difference was statistically significant and met the pre-specified test for superiority. The difference was driven by a higher rate of discontinuation due to adverse events in the Atripla arm.2, 3

  • At 96 weeks, 80% of participants on the dolutegravir-based regimen were virologically suppressed compared to 72% of participants on Atripla. Grade 2-4 treatment emergent adverse reactions occurring in 2% or more participants taking the dolutegavir-based regimen were insomnia (3%), headache (2%) and fatigue (2%).3

About HIV

HIV stands for the Human Immunodeficiency Virus. Unlike some other viruses, the human body cannot get rid of HIV, so once someone has HIV they have it for life.5-7

HIV infects specific cells of the immune system, called CD4 cells or T-cells. Over time, HIV can destroy so many of these cells that the body cannot fight off infections and disease. When this happens, HIV infection leads to Acquired Immunodeficiency Syndrome (AIDS) which is the final stage of HIV infection. There is no cure for HIV, but with early diagnosis and effective treatment most people with HIV will not go on to develop AIDS.5-7

An estimated 1.1 million people in the US are living with HIV. However, only 33 per cent are taking the medication they need.8

About Triumeq

Triumeq is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine.

Two essential steps in the HIV life cycle are replication — when the virus turns its RNA copy into DNA — and integration — the moment when viral DNA becomes part of the host cell’s DNA. These processes require two enzymes called reverse transcriptase and integrase. NRTIs and INSTIs interfere with the action of the two enzymes to prevent the virus from replicating and further infecting cells.

Dolutegravir was approved in the US in August 2013 and in Europe in January 2014 under the brand name Tivicay®. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion on the Marketing Authorisation Application (MAA) for Triumeq on 26 June 2014. Regulatory applications are also being evaluated in other markets worldwide, including Australia, Brazil andCanada.

Tivicay and Triumeq are registered trademarks of the ViiV Healthcare group of companies.

Important Safety Information (ISI) for Triumeq (abacavir, dolutegravir and lamivudine) tablets

The following ISI is based on the Highlights section of the Prescribing Information for Triumeq. Please consult the full Prescribing Information for all the labeled safety information for Triumeq.

BOXED WARNING: RISK OF HYPERSENSITIVITY REACTIONS, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY, AND EXACERBATIONS OF HEPATITIS B

See full Prescribing Information for complete boxed warning.

  • Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir-containing products.
  • Hypersensitivity to abacavir is a multi-organ clinical syndrome.
  • Patients who carry the HLA‑B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.
  • Discontinue Triumeq as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue Triumeq if hypersensitivity cannot be ruled out, even when other diagnoses are possible.
  • Following a hypersensitivity reaction to abacavir, NEVER restart Triumeq or any other abacavir‑containing product.
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.
  • Severe acute exacerbations of hepatitis B have been reported in patients who are co‑infected with Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV-1) and have discontinued lamivudine, a component of Triumeq. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment.

CONTRAINDICATIONS

  • Presence of HLA-B*5701 allele.
  • Previous hypersensitivity reaction to abacavir, dolutegravir or lamivudine.
  • Co-administration with dofetilide.
  • Moderate or severe hepatic impairment.

WARNINGS AND PRECAUTIONS

  • Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of Triumeq. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with Triumeq is recommended in patients with underlying hepatic disease such as hepatitis B or C.
  • Hepatic decompensation, some fatal, has occurred in HIV-1/Hepatitis C Virus (HCV) co‑infected patients receiving combination antiretroviral therapy and interferon alfa with or without ribavirin. Discontinue Triumeq as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both.
  • Immune reconstitution syndrome and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy.
  • Administration of Triumeq is not recommended in patients receiving other products containing abacavir or lamivudine.

ADVERSE REACTIONS

The most commonly reported (greater than or equal to 2%) adverse reactions of at least moderate intensity in treatment-naive adult subjects receiving Triumeq were insomnia (3%), headache (2%), and fatigue (2%).

DRUG INTERACTIONS

Co-administration of Triumeq with other drugs can alter the concentration of other drugs and other drugs may alter the concentrations of Triumeq. The potential drug-drug interactions must be considered prior to and during therapy.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Triumeq should be used during pregnancy only if the potential benefit justifies the potential risk.
  • Nursing mothers: Breastfeeding is not recommended due to the potential for HIV transmission.
  • Triumeq is not recommended in patients with creatinine clearance less than 50 mL per min.
  • If a dose reduction of abacavir, a component of Triumeq, is required for patients with mild hepatic impairment, then the individual components should be used.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

References:

  1. Triumeq US label
  2. Walmsley SL, Antela A, Clumeck N et al; for the SINGLE Investigators. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
  3. Walmsley S, Berenguer J, Khuong-Josses M, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA. Poster 543.
  4. Weller S, Chen S, Borland J et al. Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. JAIDS. 2014 May doi: 10.1097/QAI.0000000000000193.http://journals.lww.com/jaids/Abstract/publishahead/Bioequivalence_of_a_Dolutegravir,_Abacavir_and.97920.aspx.
  5. Centers for Disease Control and Prevention. HIV Basics. http://www.cdc.gov/hiv/basics/index.html. AccessedJuly 28, 2014.
  6. NHS Choices, HIV & AIDS Overview. http://www.nhs.uk/conditions/HIV/Pages/Introduction.aspx. AccessedJuly 28, 2014.
  7. Centers for Disease Control and Prevention. CDC Fact Sheet. HIV in the United States: The Stages of Care.http://www.cdc.gov/hiv/pdf/research_mmp_StagesofCare.pdf. Accessed July 28, 2014.
  8. Centers for Disease Control and Prevention. Today’s HIV/AIDS Epidemic.http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/TodaysEpidemic-508.pdf. Accessed July 28, 2014.

+Atripla is a registered trademark of Bristol-Meyers Squibb and Gilead Sciences, LLC.

ViiV UK/US Media enquiries:

Sebastien Desprez

Marc Meachem

+44 7920 567 707

+1 919 483 8756

GSK Global Media enquiries:

David Daley

Melinda Stubbee

+44 20 8047 5502

+1 919 483 2510

GSK Analyst/Investor enquiries:

Ziba Shamsi

Kirsty Collins (SRI & CG)

Tom Curry

Gary Davies

James Dodwell

Jeff McLaughlin

Lucy Singah

+44 20 8047 5543

+44 20 8047 5534

+1 215 751 5419

+44 20 8047 5503

+44 20 8047 2406

+1 215 751 7002

+44 20 8047 2248

GlaxoSmithKline cautionary statement regarding forward-looking statements: GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under Item 3.D “Risk factors” in the company’s Annual Report on Form 20-F for 2013.

Source: ViiV Healthcare

Related stocks: LSE:GSK NYSE:GSK NYSE:PFE

Written by asiafreshnews

August 25, 2014 at 12:48 pm

Posted in Uncategorized

Frost & Sullivan to Partner Companies in their Transformation into Lean Global Corporates with International Supply Chain Excellence Programme, Indonesia Edition 2014

leave a comment »

— A Global Best-in-Class Practices Assessment, Benchmarking, Development and Recognition Platform

 

JAKARTA, Indonesia /PRNewswire/ — With the ASEAN Economic Community (AEC) becoming a reality in 2015, economic scenarios and business dimensions are expected to change. Materials, skilled work force, services, capital, etc. will all freely move across the region without boundary constraints. This will provide more opportunities to companies and individuals, which is good news for ASEAN. At the same time, it will also require companies to be competitive at the ASEAN instead of country level. Existing manufacturing hubs likeIndonesia, Thailand, and Malaysia will try to sustain their current manufacturing advantages and other countries like Myanmar, the Philippines, and Vietnam amongst others will try to maximise the new economic environment and become new sourcing hubs in the ASEAN community.

With new opportunities and challenges knocking at the doors of corporates in Indonesia and other ASEAN nations, excelling in manufacturing and supply chain practices could very well decide on future corporate struggles. To address this rising necessity, Frost & Sullivan brings forth the International Supply Chain Excellence Programme (ISCEP), Indonesia Edition 2014. In tandem with Frost & Sullivan’s programmes currently running in India, the Gulf Co-Operation Council (GCC), Thailand and Turkey, the Indonesia Edition aims to assist companies in adopting supply chain excellence practices across industries through assessments, feedback, and benchmarking.

As part of this programme, while the top performing companies would be recognised, all assessed companies would be handed over a scorecard and an evaluation feedback would be shared. The sectorial benchmarking against global peers will be included in the feedback with more focus into the operational plans / projects of the participants. This, when integrated into the business plans in the subsequent years, would deliver maximum leverage and a clear value benefit to the participating company.

Speaking about the importance of sustaining and building further on the Manufacturing capability in the region,Eugene Van De Weerd, Country Director, Frost & Sullivan, Indonesia, said, “Manufacturing is one crucial sector that can generate huge employment opportunities in any country. Indonesia has been a favoured outsourcing hub from ASEAN and the manufacturing investments in the country continues to grow year on year. To ensure that Indonesia continues to sustain this kind of growth and outperform other regions companies will have to adopt an innovative approach to achieve excellence and sustain its competitiveness. Through the ISCEP initiative, Frost & Sullivan aims to assist companies in addressing the above challenges and build sustainable and reliable supply chain processes which will eventually impact the bottom-line of a company’s performance.”

According to Aroop Zutshi, Global President and Managing Partner, Frost & Sullivan, “The International Supply Chain Excellence Programme (ISCEP) is a must for organisations that seek to enhance their competitiveness amongst peers, and thus achieve their long term growth objectives. This programme is an effective way of adopting functional and operational best practices from across Industries and Nations. The acknowledgement benefits that will accrue to local and international top performers, will serve not only as an internal motivational tool, but can also be leveraged for effective business promotion. I invite all forward-thinking corporates to apply for this one-of-its-kind programme.”

Frost & Sullivan’s International Supply Chain Excellence Programme (ISCEP) is based on a scientific assessment of adequacy and effectiveness of the systems implemented in an organisation. This will measure the maturity of systems, their effectiveness and the continuous improvements done towards making supply chain processes reliable and capable of delivering planned results. The strength of this Programme lies in its unique Site Assessment Methodology. Every facility is examined on predefined factors that capture effectiveness and efficiency of processes such as operations, quality, customer alignment, supply chain and logistics, human resources, research & development and business financials.

The participants of this process will have global benefits and an acknowledgement process that will catalyse their reach out to customers, collaborators and partners across the world. Further, companies can leverage this international platform, by opting to be recognised in any one of the other countries covered in this Programme or a country where Frost & Sullivan has its presence, besides its own home country. (Note: Subject to Executive Committee Approval).

ISCEP Indonesia Edition is supported by Indonesian French Chamber of Commerce and Industry (IFCCI) and Supply Chain Indonesia.

If you wish to know more about the International Supply Chain Excellence Programme, Indonesia Edition 2014 or would like to register, please contact, Shena Agusta, Corporate Communications, at ISCEP@frost.com or log on to www.frost.com/ISCEP-Indonesia

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation, and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360-degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics, and emerging economies?

Contact Us:     Start the discussion
Join Us:            Join our community
Subscribe:       Newsletter on “the next big thing”
Register:         Gain access to visionary innovation

For more information, contact:

Shena Agusta
Corporate Communications – Indonesia
P: +62.21.571.0838
F: +62 21.571.3246
E: shena.agusta@frost.com

 

Source: Frost & Sullivan

Written by asiafreshnews

August 25, 2014 at 12:42 pm

Posted in Uncategorized

Vodafone Report Shows Asia Pacific Organisations Lead in Adoption of Machine-to-Machine (M2M) Solutions

leave a comment »

HONG KONG  /PRNewswire/ —

  • Surging global demand as M2M adoption increases by more than 80% in the past year
  • Africa, Middle East and Asia Pacific (AMAP) powers ahead of US and Europe in M2M take-up
  • Region expected to lead global adoption rates over the next two years
  • More than a fifth of global companies have implemented M2M, expected to be 55% in 2016
  • Consumer electronics is recognised as fastest growing sector, along with automotive

Vodafone published its second annual ‘M2M Adoption Barometer’, a global survey of the machine-to-machine (M2M) market, which finds that companies in Asia Pacific were among the leaders in M2M adoption globally. In 2014, 27% of AMAP based companies on average have adopted M2M solutions  a 15 point increase over 2013. Average adoption rates were 21% in Europe and 17% in the Americas.

M2M, which connects previously isolated machines or devices to the internet to make the ‘Internet of Things’ possible, is now a mainstream solution as 22% of organisations on average globally have adopted M2M, an impressive increase of over 80% on last year; the survey findings suggest.

The survey, carried out by Circle Research, captured the views of more than 600 executives 38% of whom were from the AMAP region — involved in setting M2M strategy in seven key industries across 14 countries, making it one of the leading global surveys of M2M implementation.

The 2013 Vodafone M2M Adoption Barometer report had predicted that the US will be overtaken by the AMAP region as the geography with the widest adoption of M2M. The 2014 survey now predicts that the AMAP region will continue to lead the rest of the world over the next couple of years  with adoption expected to hit 48% on average across companies based in this region in 2015. This year’s report also suggests that by 2016 the gap will be negligible with all regions close to 55% average for adoption.

Globally three sectors have emerged as front runners in M2M with nearly 30% adoption rates: automotive, consumer electronics, and energy and utilities. Vodafone’s report shows that the consumer electronics sector is at the forefront of a shift from the warehouse to the living room. Automotive is the most mature of the sectors where M2M is now seen as an enabler for additional services such as remote maintenance and infotainment. M2M adoption in energy and utilities is also growing rapidly as ‘smart’ home and office services such as intelligent heating and connected security gain popularity.

While more firms are seeing a return on investment from M2M than last year 46% of respondents cited a ‘significant increase’ compared with 36% in 2013  there are still some barriers to adoption, including managing security concerns and the challenges of global deployment.

Director of Machine-to-Machine in Asia Pacific, Vodafone, Niklas Ekarv said: “This year’s report findings leaves no doubt that momentum is accelerating as companies in Asia Pacific begin to realise the commercial potential of the Internet of Things. Machina Research expects M2M connections in Asia to grow at a CAGR of 20% till 2023*. This technology is transforming whole industries across Asia as companies find new ways to operate and engage with their customers. Greater China is expected to dominate Asian M2M revenues as per Machina Research; followed by Japan, India, Korea and Australia. Vodafone has invested in capabilities across Asia Pacific to become the provider of choice for M2M solutions.”

Principal Analyst at Machina Research, Alex Chau, said, “We estimate that the market in Asia Pacific is expected to grow to over 9.4 billion connections by 2023 and is expected to be worth over US$679 billion in revenues a 4x multiplier increase over 2013. Vodafone’s M2M Barometer report indicates just how fast M2M is being adopted. M2M technologies are being used more and more to drive efficiency and add new features, giving companies a competitive edge. It is also starting to facilitate new ways of working, fundamentally changing how organisations do business and how they serve their customers.”

The report is available to download from https://m2m.vodafone.com/barometer2014.

*Source – Machina Research’s M2M Forecast Database

Notes to editors:

About Vodafone Machine-to-Machine (M2M)

Vodafone Machine-to-Machine (M2M) connects previously isolated machines or devices to the internet, delivering new functionality and enhanced services without the need for human intervention. Supported by more than 250 dedicated employees, Vodafone’s global M2M platform makes it easy for global businesses to manage centrally M2M deployments across multiple territories, with greater control and at a lower cost than previously possible. In 2014 Vodafone was named global M2M leader by Machina Research, for the third year in a row. For more information, please visit: https://m2m.vodafone.com/home/.

About Vodafone

Vodafone is one of the world’s largest telecommunications companies and provides a range of services including voice, messaging, data and fixed communications. Vodafone has mobile operations in 27 countries, partners with mobile networks in 48 more, and fixed broadband operations in 17 markets. As of 31 March 2014, Vodafone had 434 million mobile customers and 9 million fixed broadband customers. For more information, please visit: www.vodafone.com

Media Relations

Text 100 Hong Kong
Clare Mui / Wolfie Zhao
+852-2821-8692

Text100 Singapore
Hong Mei Yu / Gary Ng
+65-6603-9000
singaporevodafone@text100.com

Source: Vodafone

Written by asiafreshnews

August 25, 2014 at 10:18 am

Posted in Uncategorized